Itamar Medical’s Endo-PAT2000 now available in Italy

Itamar Medical, an international medical technology company developing noninvasive diagnostic systems using the Peripheral Arterial Tone (PAT™) Signal, announced today its distribution agreement with EndoTech SPA to bring Itamar Medical’s patented Endo-PAT2000, the first simple, office-based diagnostic test for the assessment of endothelial function, to the Italian market.

EndoTech SPA, based in Como, Italy, specializes in the distribution and launch of innovative medical instrumentation technologies in Italy, and features extensive knowledge and experience in the cardiovascular field. This ideal partnership will allow Itamar Medical to reach new market and distribution goals for the Endo-PAT2000. With powerful sales force that reaches every corner of the Italian market, EndoTech SPA offers the optimized customer, scientific, and technical support for the continued success of its product portfolio, which now includes the Endo-PAT2000.

“We are thrilled to partner with EndoTech SPA in our efforts to bring the Endo-PAT2000 to Italy,” said Israel Schreiber, President and CEO of Itamar Medical. “This new cooperative agreement paves the way for patients in Italy to get tested with the Endo-PAT2000, providing them with a comprehensive picture of their endothelial cell function, a critical factor in cardiac health.”

For years, endothelial function assessment was a privilege reserved solely to vascular research labs, as there was no easy-to-use, reproducible assessment method. Itamar Medical has developed the first inexpensive, office-based diagnostic test for endothelial function. The Endo-PAT2000 is a noninvasive device that measures endothelial function by using bio-sensors mounted on patients’ fingers. These sensors measure minute changes in vascular tone using the PAT Signal.

About Itamar Medical

Itamar Medical (TASE: ITMR) is a medical technology company developing noninvasive diagnostic systems using Peripheral Arterial Tone (PAT™) signal, including the Watch-PAT™ systems for the diagnosis of sleep related breathing disorders and the Endo-PAT™ systems for assessment of endothelial function, a condition recognized as an early stage of cardiovascular and cerebrovascular diseases. For further information see http://www.itamar-medical.com.

Media Contacts

Marissa Levy
Account Executive
NCSM Strategic Marketing
+972-2-563-7527
Marissa@ncsm.co.il

Livnat Zvili-Ojalvo
Itamar Medical
Marketing and Sales Coordinator
+972-4-617-7000
Zlivnat@itamar-medical.com

L Finnsson

Recent Posts

Base Station RF Power Amplifier Market to Experience Significant Growth Amid 5G Expansion and Rising Mobile Device Adoption

October 24, 2024 – Metastat Insights – The global Base Station RF Power Amplifier market…

4 weeks ago

World Leaders in Aeronautics, Defence, and Aerospace to Attend the Marrakech Air Show 2024

London, 23rd October 2024 – Under the High Patronage of His Majesty King Mohammed VI,…

4 weeks ago

Sunshine State Dentistry of Boynton Beach Launches New Website to Provide Patients with a Seamless Digital Experience

Boynton Beach, FL – September 10, 2024 – Sunshine State Dentistry of Boynton Beach, led…

2 months ago

Metastat Insights Projects Significant Growth in Tattoo Supplies Market by 2031

Sep 10, 2024 – Dallas, TX – A new report by Metastat Insights reveals that…

2 months ago

RIMC Celebrates 20th Anniversary, Bringing Global Digital Marketing Insights to Iceland

Reykjavik, Iceland – September 2024 – The Reykjavik Internet Marketing Conference (RIMC), Iceland's longest-running digital…

3 months ago

The Inspiring Journey of Sleipnir Tours

Hafnarfjörður, Iceland, July 16, 2024 – One evening in Iceland, Ástvaldur, the founder of Sleipnir…

4 months ago